For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched clinical trial of this exact supplier preparation was verified.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Traditional use and ingredient marketing are not clinical efficacy evidence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
Cistanche tubulosa extract: randomized mobility study (2021)
26 analyzed participants with mild or presymptomatic locomotive syndrome; 12-week blinded placebo-controlled study.
Reported findings. No positive effect established on the stated primary outcome.
Nonresponse. Gait measures improved in an older subgroup; muscle mass did not change.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Small sample and subgroup result. Exact extract standardization matters; neither generalized anabolic benefit nor commercial-product equivalence is established.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
Cistanche tubulosa extract: randomized mobility study (2021)
Placebo-controlled locomotor-function study; positive walking findings restricted to older subgroups.
Reported findings. Some walking findings were positive in older subgroups.
Nonresponse. Full-sample physical-function comparisons were null; muscle mass unchanged.
Harms. No adverse effects observed in the study; general safety not established.
Limits. Species/extract-specific study, not complete evidence for generic Cistanche supplements. Subgroup findings require cautious interpretation.
Preparation: C. tubulosa ethanol extract containing 5.41% acteoside and 17.48% echinacoside; commercial species/extract equivalence unverified. Route: oral
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
<i>Cistanche tubulosa</i>-<i>Ginkgo biloba</i> combination enhances memory via cortico-cerebellar reorganization: a randomized controlled trial.
117 healthy adults randomized double-blind for30days; MRI subset15.
Reported findings. Several memory outcomes favored the combination versus placebo.
Nonresponse. Portrait-memory between-group result nonsignificant, p0.065; meaningless-graphics recognition declined in both groups, less with combination.
Harms. No spontaneously reported adverse events during30days; limited surveillance does not establish comprehensive safety.
Limits. Cannot separate Cistanche contribution from Ginkgo or establish catalog extract equivalence. MRI correlations and subset15 do not establish a causal neural mechanism. Study2019-2020 with registration identifierChiCTR2400084102; prospective registration not established.
Preparation: Oral Nutrilite/Amway Cistanche tubulosa plus Ginkgo biloba standardized-extract combination; not catalog Cistanche alone. Route: Oral combined tablets; not isolated Cistanche or injectable peptide exposure.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.